Lars Ekman's Net Worth
$14.6 Million
Who is Lars Ekman?
Lars Ekman has an estimated net worth of $14.6 Million. This is based on reported shares across multiple companies, which include SOPHIRIS BIO INC., AMARIN CORP PLC\UK, ARYx Therapeutics, Inc., PROTHENA CORP PUBLIC LTD CO, Ultragenyx Pharmaceutical Inc., Spark Therapeutics, Inc., INTERMUNE INC, and Ocera Therapeutics, Inc..
SEC CIK
Lars Ekman's CIK is 0001376117
Past Insider Trading and Trends
2019 was Lars Ekman's most active year for acquiring shares with 19 total transactions. Lars Ekman's most active month to acquire stocks was the month of April. 2019 was Lars Ekman's most active year for disposing of shares, totalling 28 transactions. Lars Ekman's most active month to dispose stocks was the month of August. 2019 saw Lars Ekman paying a total of $1,348,451.43 for 437,263 shares, this is the most they've acquired in one year. In 2019 Lars Ekman cashed out on 839,321 shares for a total of $7,882,606.06, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
SOPHIRIS BIO INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
| -94.89% | -9.66K |
$0.47 | -$4,541.61 | 520 |
Dec 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AMARIN CORP PLC\UK (AMRN) Snapshot price: $0.6094
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 13
| |||
Form 4
|
—
|
0
|
$16.88 | -$190,919.46 |
0
|
Scheduled
|
Nov 12
| ||
Form 4
|
—
|
0
|
$16.20 | -$23,070.08 |
0
|
Scheduled
|
Nov 5
| ||
Form 4
|
—
|
0
|
$9.27 | -$1,045,442.77 |
0
|
Scheduled
|
Sep 3
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
$11.68 | -$2,608,161.45 |
0
|
Scheduled
|
Mar 4
| ||
Form 4
| -100.00% | -40.00K |
$9.16 | -$2,323,060.87 |
0
|
Scheduled
|
Jan 10
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 4
|
∞
| 40K |
$1.80 | $72,000.00 | 40K |
Nov 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARYx Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
PROTHENA CORP PUBLIC LTD CO (PRTA) Snapshot price: $20.33
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
$31.20 | -$784,911.49 | 243 |
Scheduled
|
Jan 3
| ||
Form 4
|
—
|
0
|
$34.01 | -$873,910.30 | 243 |
Scheduled
|
Dec 1
| ||
Form 4
|
—
|
0
|
$34.65 | -$894,168.34 | 243 |
Scheduled
|
Nov 1
| ||
Form 4
|
—
|
0
|
$33.97 | -$872,592.02 | 243 |
Scheduled
|
Oct 3
| ||
Form 4
|
—
|
0
|
$27.25 | -$1,319,838.88 | 243 |
Scheduled
|
Sep 28
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
$39.88 | -$2,008,133.21 | 243 |
Nov 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ultragenyx Pharmaceutical Inc. (RARE) Snapshot price: $55.24
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +22.85% | 3.3K |
—
|
—
| 17.75K |
Jun 24
| |||
Form 4
| +17.44% | 2.15K |
—
|
—
| 14.45K |
Jun 24
| |||
Form 4
| +26.15% | 2.55K |
—
|
—
| 12.3K |
Jun 26
| |||
Form 4
| +44.44% | 3K |
—
|
—
| 9.75K |
Jun 11
| |||
Form 4
| +80.00% | 3K |
—
|
—
| 6.75K |
Jun 19
| |||
Form 4
| +100.00% | 1.88K |
—
|
—
| 3.75K |
Jun 22
| |||
Form 4
|
∞
| 1.88K |
—
|
—
| 1.88K |
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||